About TBC1 domain family member 17
TBC1 domain family member 17 (TBC1D17) is a protein
from Homo sapiens identified by UniProt accession
Q9HA65, 648 residues long.
MolForge cross-references it against 0 known binders and
7 disease associations.
Target properties
| Protein name | TBC1 domain family member 17 |
| UniProt accession | Q9HA65 |
| Gene | TBC1D17 |
| Organism | Homo sapiens |
| Length | 648 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (7)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- lean body mass · score 0.05
- Vitiligo · score 0.01
- cutaneous melanoma · score 0.00
- neoplasm · score 0.00
- Stillbirth · score 0.00
- cancer · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9HA65-F1 | alphafold | PREDICTED | 72.57 | — |
Amino-acid sequence (648 residues)
MEGAGYRVVF EKGGVYLHTS AKKYQDRDSL IAGVIRVVEK DNDVLLHWAP VEEAGDSTQI LFSKKDSSGG DSCASEEEPT FDPGYEPDWA VISTVRPQLC HSEPTRGAEP SCPQGSWAFS VSLGELKSIR RSKPGLSWAY LVLVTQAGGS LPALHFHRGG TRALLRVLSR YLLLASSPQD SRLYLVFPHD SSALSNSFHH LQLFDQDSSN VVSRFLQDPY STTFSSFSRV TNFFRGALQP QPEGAASDLP PPPDDEPEPG FEVISCVELG PRPTVERGPP VTEEEWARHV GPEGRLQQVP ELKNRIFSGG LSPSLRREAW KFLLGYLSWE GTAEEHKAHI RKKTDEYFRM KLQWKSVSPE QERRNSLLHG YRSLIERDVS RTDRTNKFYE GPENPGLGLL NDILLTYCMY HFDLGYVQGM SDLLSPILYV IQNEVDAFWC FCGFMELVQG NFEESQETMK RQLGRLLLLL RVLDPLLCDF LDSQDSGSLC FCFRWLLIWF KREFPFPDVL RLWEVLWTGL PGPNLHLLVA CAILDMERDT LMLSGFGSNE ILKHINELTM KLSVEDVLTR AEALHRQLTA CPELPHNVQE ILGLAPPAEP HSPSPTASPL PLSPTRAPPT PPPSTDTAPQ PDSSLEILPE EEDEGADS
Explore TBC1 domain family member 17 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets